by Peter Ciszewski | Nov 11, 2019
New data from a phase III clinical trial may indicate that a drug used in combination therapy for multiple myeloma may be effective as a single-agent therapy. The drug is Ninlaro (ixazomib) is an oral proteasome inhibitor currently approved by the U.S. Food and Drug...
by Peter Ciszewski | Nov 8, 2019
Gary Joseph Lelli, MD, of the Department of Ophthalmology at Weill Cornell Medicine talks about the incidence and treatment options for thyroid eye disease due to Graves’ disease. Graves’ disease is an immune system disorder that results in the...
by Peter Ciszewski | Nov 7, 2019
“We are almost like the original managed care plan,” stated Joe Pugliese of the Hemophilia Alliance. The group started in the 1970s when the hemophilia patient community went to Congress and said “we need to have a comprehensive care model for adequately...
by Peter Ciszewski | Nov 6, 2019
Clinical-stage biopharma company X4 Pharmaceuticals announced the initiation of a Phase 1b clinical trial of mavorixafor (X4P-001) for the treatment of Severe Congenital Neutropenia (SCN), a group of rare blood disorders characterized by abnormally low levels of...
by Peter Ciszewski | Nov 5, 2019
Femida Gwady-Sridhar, PhD, founder of Pulse Infoframe talks about the need for better collaboration between patient groups and researchers in regard to collecting and using data more effectively and efficiently. “For several years I did research in cardiology...
